BRCA2 and neoplasm: For example, BRCA2 mutant tumour cell lines that become PARPi resistant after long term in vitro PARPi exposure develop reversion mutations (Glossary) [22], i.e. secondary mutations in BRCA2 that compensate for the original pathogenic mutation.